GlassScriptPhysician profile
Erin M Doherty
NPI 1780657080
$4,672.35
in general payments reported to CMS, 2019-2025
24 companies · $1,146 in 2025
The $1,146 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $199 · 2022: $1,393 · 2023: $839 · 2024: $1,095 · 2025: $1,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,002 · Education: $79.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,001.65 |
| Education | $79.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $910.17 | 2021-2025 | |
| Leo Pharma INC. | $657.54 | 2022-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $532.49 | 2021-2025 | Tremfya, Simponi, Stelara |
| Sun Pharmaceutical Industries INC. | $441.19 | 2022-2025 | Ilumya, Winlevi, Absorica Ld |
| Lilly USA, LLC | $294.70 | 2022-2025 | Olumiant, Taltz, Ebglyss |
| Incyte Corporation | $264.97 | 2021-2025 | Opzelura |
| Ucb, INC. | $253.57 | 2022-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $190.17 | 2021-2025 | |
| Genzyme Corporation | $163.25 | 2021-2024 | |
| Pfizer INC. | $148.43 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $120.79 | 2022-2025 | Sotyktu |
| Almirall LLC | $111.36 | 2022-2025 | Seysara, Klisyri |
| Regeneron Healthcare Solutions, INC. | $106.83 | 2022-2025 | Dupixent, Libtayo |
| Amgen INC. | $100.28 | 2022-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $92.20 | 2023-2024 | Vtama |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.91 | 2024-2025 | Spevigo |
| Botanix Sb INC | $46.60 | 2025 | Sofdra |
| Journey Medical Corporation | $41.70 | 2022-2024 | |
| Galderma Laboratories, L.P. | $30.55 | 2022-2023 | Aklief |
| Verrica Pharmaceuticals INC. | $25.06 | 2024 | Ycanth |
| Organon LLC | $21.11 | 2025 | Nexplanon, Vtama |
| Solta Medical, A Division of Bausch Health US, LLC | $18.70 | 2025 | |
| Epi Health, LLC | $15.93 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $12.85 | 2023 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Doherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.